JP2006512899A5 - - Google Patents

Download PDF

Info

Publication number
JP2006512899A5
JP2006512899A5 JP2004526901A JP2004526901A JP2006512899A5 JP 2006512899 A5 JP2006512899 A5 JP 2006512899A5 JP 2004526901 A JP2004526901 A JP 2004526901A JP 2004526901 A JP2004526901 A JP 2004526901A JP 2006512899 A5 JP2006512899 A5 JP 2006512899A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004526901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512899A (ja
JP4528121B2 (ja
Filing date
Publication date
Priority claimed from GB0218229A external-priority patent/GB0218229D0/en
Priority claimed from GB0218230A external-priority patent/GB0218230D0/en
Priority claimed from GB0218232A external-priority patent/GB0218232D0/en
Priority claimed from GB0218234A external-priority patent/GB0218234D0/en
Application filed filed Critical
Priority claimed from PCT/EP2003/008749 external-priority patent/WO2004014953A2/en
Publication of JP2006512899A publication Critical patent/JP2006512899A/ja
Publication of JP2006512899A5 publication Critical patent/JP2006512899A5/ja
Application granted granted Critical
Publication of JP4528121B2 publication Critical patent/JP4528121B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004526901A 2002-08-06 2003-08-05 抗ミエリン関連糖タンパク質（ｍａｇ）抗体 Expired - Fee Related JP4528121B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0218229A GB0218229D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218230A GB0218230D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218232A GB0218232D0 (en) 2002-08-06 2002-08-06 Antibodies
GB0218234A GB0218234D0 (en) 2002-08-06 2002-08-06 Antibodies
PCT/EP2003/008749 WO2004014953A2 (en) 2002-08-06 2003-08-05 Anti-myelin associated glycoprotein (mag) antibodies

Publications (3)

Publication Number Publication Date
JP2006512899A JP2006512899A (ja) 2006-04-20
JP2006512899A5 true JP2006512899A5 (enExample) 2006-08-31
JP4528121B2 JP4528121B2 (ja) 2010-08-18

Family

ID=31721633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004526901A Expired - Fee Related JP4528121B2 (ja) 2002-08-06 2003-08-05 抗ミエリン関連糖タンパク質（ｍａｇ）抗体

Country Status (23)

Country Link
US (2) US7612183B2 (enExample)
EP (1) EP1526868B1 (enExample)
JP (1) JP4528121B2 (enExample)
KR (1) KR101078459B1 (enExample)
CN (1) CN100542607C (enExample)
AR (1) AR040778A1 (enExample)
AU (1) AU2003255390B2 (enExample)
BR (1) BR0312456A (enExample)
CA (1) CA2494008C (enExample)
CY (1) CY1114919T1 (enExample)
DK (1) DK1526868T3 (enExample)
ES (1) ES2440652T3 (enExample)
IL (1) IL165478A (enExample)
IS (1) IS7576A (enExample)
MX (1) MXPA05001468A (enExample)
MY (1) MY148409A (enExample)
NO (1) NO333876B1 (enExample)
NZ (1) NZ537123A (enExample)
PL (1) PL211014B1 (enExample)
PT (1) PT1526868E (enExample)
SI (1) SI1526868T1 (enExample)
TW (1) TWI323265B (enExample)
WO (1) WO2004014953A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
EP2021373A4 (en) * 2006-05-31 2010-06-02 Hanwa Chemical Corp MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
AU2007313685C1 (en) 2006-11-02 2015-09-17 Genentech, Inc. Humanized anti-Factor D antibodies
EP2212431A4 (en) * 2007-10-16 2011-05-11 Nuvelo Inc ANTIBODY AGAINST IREM-1
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TW201012489A (en) 2008-05-06 2010-04-01 Glaxo Group Ltd Encapsulation of biologically active agents
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
BRPI1007371A2 (pt) * 2009-01-29 2018-03-27 Abbott Lab proteínas de ligação a il-1
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
BR112012013734A2 (pt) 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
NZ605260A (en) * 2010-06-14 2013-12-20 Joseph King Allan Anti-vegf antibodies and uses thereof
US8974782B2 (en) * 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
EP2807192B1 (en) 2012-01-27 2018-04-18 Abbvie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
WO2015091144A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Improved recombinant polypeptide production methods
SMT202100231T1 (it) 2014-03-13 2021-05-07 Univ Basel Ligandi di carboidrato che si legano ad anticorpi igm contro glicoproteina associata a mielina
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
UA123053C2 (uk) 2015-06-24 2021-02-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
AU2016323377B2 (en) 2015-09-16 2021-04-15 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
EP3355920A4 (en) * 2015-09-29 2019-05-15 Celgene Corporation PD-1 BINDING PROTEINS AND METHOD OF USE THEREOF
MA43023A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
AU2017329024A1 (en) 2016-09-19 2019-03-21 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
CN109481673A (zh) * 2017-09-12 2019-03-19 中国科学院苏州纳米技术与纳米仿生研究所 促进脑损伤神经修复的组合物及其应用与评价方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK84787D0 (da) 1987-02-19 1987-02-19 Axel Olsen Listesystem til foering af elektriske stroemforsynings- og/eller svagstroemsledere
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5154927A (en) * 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
FI93513C (fi) 1993-11-04 1995-04-25 Matti Kangasvuori Ketju sekä menetelmä ketjun tekemiseksi
WO1995019790A1 (en) * 1994-01-25 1995-07-27 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
KR19990007893A (ko) 1995-04-19 1999-01-25 론 코헨 중추신경계（ｃｎｓ） 축삭 성장 모듈레이터, 이를 구현 및 사용하는 조성물, 세포 및 방법
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5792743A (en) 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
DE69633336T2 (de) 1995-06-27 2005-09-22 Research Foundation Of Cuny Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
CN1196733A (zh) * 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
AU6858596A (en) 1995-08-25 1997-03-19 Johns Hopkins University School Of Medicine, The Compounds for stimulating nerve growth
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CA2266339A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
DE69818106T2 (de) 1997-10-28 2004-06-17 The University Of British Columbia, Vancouver Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung
JP2002507544A (ja) * 1997-11-14 2002-03-12 ユーロ−セルティーク，エス．エイ． 抗イディオタイプ応答を引き出す能力が増強された改変型の抗体
AU3134799A (en) * 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
PT1098972E (pt) 1998-07-22 2010-12-14 Smithkline Beecham Ltd Proteína semelhante a proteína especificamente neuroendócrina e adnc codificante
KR20010075108A (ko) * 1998-09-14 2001-08-09 라즈 외스테르가아드 페데르센 기능적 면역글로불린 수퍼패밀리 단백질을 생산하는 방법
CN101684155A (zh) 1998-11-06 2010-03-31 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
CA2361124A1 (en) 1999-01-22 2000-07-27 Matthew John During Vaccine-mediated treatment of neurological disorders
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
JP4656478B2 (ja) 2000-02-22 2011-03-23 株式会社医学生物学研究所 抗体ライブラリー
GB0103174D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Similar Documents

Publication Publication Date Title
JP2006512899A5 (enExample)
CA2494008A1 (en) Anti-myelin associated glycoprotein (mag) antibodies
RU2504551C2 (ru) Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста
JP2009511480A5 (enExample)
RU2006123481A (ru) Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
IL302078A (en) Anti-ccr8 monoclonal antibodies and uses thereof
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2020500538A5 (enExample)
JP2012504955A5 (enExample)
JP2020517249A5 (enExample)
PE20160999A1 (es) Metodos para administrar anticuerpos anti-tnf-alfa
JP2003525061A5 (enExample)
RU2017104815A (ru) Молекулы со специфичностью в отношении cd79 и cd22
JP2011506483A5 (enExample)
JP2018535650A5 (enExample)
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2003528052A5 (enExample)
JP2010516229A5 (enExample)
RU2011128332A (ru) Антитело против siglec-15
JP2008538564A5 (enExample)
JP2019522961A5 (enExample)
RU2008129080A (ru) Средства и способы лечения опухолевых заболеваний
JP2010526028A5 (enExample)
JP2012532851A5 (enExample)